New treatment plan brings good news to patients with neuralgia after radiotherapy
December 19, 2018 Source: Science Network
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];
Professor Tang Yamei, Professor of Sun Yat-sen Memorial Hospital, Sun Yat-Sen University
Professor Tang Yamei's recent photo
On December 17, the reporter learned from Sun Yat-sen Memorial Hospital of Sun Yat-sen University that the research of the team's Tang Yamei team showed that pregabalin can effectively improve the neuralgia after radiotherapy and provide a new treatment for patients with neuralgia after radiotherapy. Related research was published online November 20 in the American Journal of Clinical Oncology.
The "Lancet and Tumor" special commentary pointed out that this clinical study is the first randomized controlled clinical study to study the efficacy of chronic pain medication after radiotherapy for head and neck tumors in the world. It is also the first time since the publication of the Journal of Clinical Oncology. The leading clinical research results on the complications of nerve injury after radiotherapy of head and neck tumors provide reliable evidence-based medical evidence for the treatment of neuralgia after radiotherapy.
"Declaration of war" after neuralgia after radiotherapy
Head and neck cancer, especially nasopharyngeal carcinoma, is a high-risk tumor in South China, and radiotherapy is one of the most important treatments. However, due to radiation damage to nerve tissue, chronic pain caused by radiotherapy has long afflicted patients. How to solve neuralgia after radiotherapy has become a concern of many medical experts at home and abroad.
Tang Yamei's team spent five years exploring the effectiveness and safety of pregabalin for neuropathic pain after radiotherapy for head and neck tumors. The team gave the treatment group and the control group oral pregabalin and placebo on a double-blind basis. During the administration, the pain index, functional activity impairment, mood disorder and quality of life were assessed, and side effects were recorded. What happened.
Statistical analysis showed that the pain index of patients in the pregabalin group decreased significantly compared with the baseline at the 16th week after treatment, and the pain index decreased by 37%. At the same time, it effectively improved the functional activity disorder and adverse emotion caused by pain, and significantly improved the quality of life of patients. Further subgroup analysis suggested that the effect of pregabalin on pain relief was not affected by age, previous tumors, and radiation brain injury treatment options.
"For patients with long-term pain after radiotherapy, the results of the study will bring them the gospel, allowing clinicians to have a weapon for treatment." Tang Yamei said that the success of this clinical study is attributed to rigorous experimental design. Comprehensive and reasonable evaluation methods and the unremitting efforts of the members of the research team.
New treatments bring the gospel to patients
“Many studies have focused only on acute pain after radiotherapy, but less attention has been paid to chronic pain after radiotherapy, but this is a major problem that has long plagued patients.†Tang Yamei said that patients with head and neck cancer may experience acute pain and chronic pain after radiotherapy. The pathogenesis of the two is different. The chronic pain after radiotherapy is mainly caused by radiation-damaged nerve tissue and belongs to neuropathic pain.
Chronic pain after radiotherapy in patients with head and neck cancer can be as high as 31% in tumor radiotherapy. Neuropathic pain after radiotherapy seriously affects patients' daily life and functional activities, and may even lead to emotional disorders such as anxiety and depression, which seriously reduce the quality of life of patients. Prior to this, there were no randomized controlled clinical studies in this direction in the world.
Tang Yamei is committed to the clinical and basic research of radiation nerve injury for more than ten years. During clinical diagnosis and treatment, she found that pregabalin has a faster onset, more significant effect, and more tolerance than other drugs for treating neuropathic pain. Good, but lack evidence-based medical evidence to support. To clarify the effectiveness of the treatment, she set out to prepare a clinical study to answer the question.
After repeated discussions, adjustments and optimizations on the research protocol, the clinical study of neuropathic pain treatment after radiotherapy led by Tang Yamei was initiated in 2013 and completed in 5 years. Its research indicates that pregabalin can effectively improve neuralgia after radiotherapy, and provides a new treatment for patients with neuralgia after radiotherapy.
Professor Marieke van den Beuken-van Everdingen of the University of Maastricht in the Netherlands pointed out in the comments of "The Lancet and Tumor": "This clinical study is a good proof that pregabalin can effectively alleviate head and neck cancer after radiotherapy Neuropathic pain."
Insulin Syringes Needle,Disable Syringe,Monoject Syringe,10 Ml Syringe
FOSHAN PHARMA CO., LTD. , https://www.full-pharma.com